Virus Protease Inhibitor

HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC₅₀ of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC₅₀ of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity.

NS2B/NS3-IN-5 (Compound 25b) is an allosteric DENV2 and ZIKV NS2B/NS3 protease inhibitor with IC₅₀ values of 0.67 µM and 4.38 µM against ZIKV and DENV2 NS2B/NS3 proteases, respectively.

Tercatain is a COVID-19 main protease inhibitor with antibacterial activity. Tercatain exhibits antibacterial activity against Ralstonia solanacearum. Tercatain can be used for the research of COVID-19, and bacterial infections.

NZ-804 is an orally active inhibitor for SARS-CoV-2 main protease Mpro with an IC₅₀ of 8.9 nM. NZ-804 inhibits the SARS-CoV-2 replication in HeLa-hACE2 cell with an EC₅₀ of 14 nM. NZ-804 exhibits board-spectrum antiviral activity aganst multiple CoVs. NZ-804 diminishes virus replication in mouse and hamster model.

Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13  µM, K_i = 8.8  nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model.

Artesunate-d₃ is the deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).

SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds.

SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC₅₀ of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC₅₀ = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC₅₀ of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations.

CG-0988 is a selective SARS-CoV-2 3C-like protease (3CL^pro) inhibitor with an IC₅₀ of 8.5 nM. CG-0988 functionally inhibits SARS-CoV-2 3CL^pro, blocks SARS-CoV-2 replication, and exerts antiviral activity against SARS-CoV-2 variants. CG-0988 can be used in research related to coronavirus disease 2019 (COVID-19).

ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi.

Schisandrin A (Standard) is the analytical standard of Schisandrin A. This product is intended for research and analytical applications. Schisandrin A inhibits CYP3A activity with an IC₅₀ of 6.60 μM and Ki of 5.83 μM, respectively.

(M)-AVI-4773 is an orally active, blood-brain barrier permeable coronaviruses M^Pro inhibitor with an IC₅₀ of 2.5 nM aginst SARS-CoV-2 M^Pro. (M)-AVI-4773 produces a rapid onset antiviral effect in mouse models of MERS-CoV and SARS-CoV-2 infection.

3CLPro-IN-3 (Compound A36) is an inhibitor for SARS-CoV-2 3CLpro with IC₅₀ of 51.3 nM. 3CLPro-IN-3 exhibits antiviral activity against human coronavirus 229E, OC43 and mouse hepatitis virus MHV.

Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.

NPI52 (Compound E1) is a foot-and-mouth disease virus 3C protease (FMDV 3Cpro) inhibitor, with IC₅₀ values of 0.05 and 0.11 µM in FRET and cell-based assay, respectively.

MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC₅₀ of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC₅₀ values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection).

Probucol-d₆ is deuterium labeled Probucol. Probucol (DH-581) is an anti-hyperlipidemic agent by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

Artesunate-d₄ is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).

Bevirimat (Standard) is the analytical standard of Bevirimat. This product is intended for research and analytical applications. Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].

ZIKV-IN-1 is a potent zika virus inhibitor with an EC₅₀ of 2.8 μM and EC₉₀ of 6.8 μM. ZIKV-IN-1 shows anti-ZIKV activity with low cytotoxicity. ZIKV-IN-1 shows a strong affinity to ZIKV RdRp domain. ZIKV-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.